A healthcare hedge fund just locked in gains on one of its biggest winners—here’s what that move really signals.
This year’s summit will focus on innovation and will highlight new technologies that can strengthen every stage of kidney care, from early detection to post-transplant management. The increasing role ...
Shares of Ligand Pharmaceuticals are absolutely flying as investors line up behind the company's unique royalty-based ...
Ligand is increasing its 2025 full year financial guidance. The Company now expects total core revenue of $225 million to $235 million (previously $200 million to $225 million) and core adjusted ...
Michael Burry Shutters Scion Asset Management, Renews AI Bubble Warning With Lord of the Rings Meme (International Business ...